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Bortezomib for advanced Bronchioloalveolar Carcinoma (BAC): 
a California-Pittsburgh Cancer Consortium multicenter phase II 
study
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Background: BAC accounts for approximately 3-5% of all cases of 
non-small cell lung cancer (NSCLC). An additional 20% of patients 
with adenocarcinoma have a BAC component. The optimal treat-
ment of advanced BAC is yet to be deﬁned, though inhibitors of the 
epidermal growth factor receptor pathway (EGFR) have demonstrated 
promising efﬁcacy. Bortezomib, a novel proteosome inhibitor, has 
demonstrated single agent activity against NSCLC. We conducted a 
phase II study to evaluate the efﬁcacy of bortezomib for patients with 
advanced BAC or adenocarcinoma with BAC features. A novel weekly 
schedule of bortezomib was utilized for the study.
Methods: Eligibility criteria were: histological conﬁrmation of diag-
nosis, ≤ 1 prior chemotherapy regimen, ECOG PS 0-2, presence of 
measurable disease, adequate bone marrow, hepatic and renal function 
and willingness to sign informed consent. Prior EGFR inhibitor therapy 
was permitted (not considered as a chemotherapy regimen for eligibil-
ity). Bortezomib (1.6 mg/m2) was administered intravenously on days 
1 and 8 of every 3 week cycle. Treatment was continued until disease 
progression or unacceptable toxicity. The primary endpoint was deter-
mination of the response rate. Secondary endpoints included survival 
and toxicity assessment.
Results: Twenty four patients have been enrolled to date: females-12; 
PS 0-9; PS 1-13; never smokers-8; prior therapy-16. Treatment was 
tolerated well and a median of 3 cycles of therapy were administered. 
Nine patients are still on treatment. Salient toxicities (grades 2/3) (N) 
attributable to treatment are: neutropenia-2/0; fatigue-4/2; diarrhea-2/2; 
nausea-1/0; emesis-1/0 and sensory neuropathy-1/0. One patient experi-
enced partial response (4.5%) and 14 had stable disease (64%) out of 
22 evaluable patients (clinical beneﬁt rate - 69%). The median survival 
is 9.4 months. Most patients were censored at a median follow up of 5 
months for the purposes of this analysis. Accrual to the study continues.
Conclusions: The preliminary results of our study demonstrate modest 
anti-cancer activity with bortezomib in patients with advanced BAC, 
including those who had disease progression with an EGFR inhibitor. 
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Sunitinib in combination with gemcitabine plus cisplatin for 
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from a phase I dose escalation study
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Background: Sunitinib malate is an oral, multitargeted tyrosine 
kinase inhibitor of VEGFRs, PDGFRs, KIT, RET, and FLT3, approved 
internationally for the treatment of advanced renal cell carcinoma 
and imatinib-resistant or -intolerant gastrointestinal stromal tumor. 
Single-agent sunitinib is also active in advanced NSCLC after failure of 
platinum-based therapy, resulting in an objective response rate of 11% 
(Socinski, ESMO 2006). We report preliminary results from a phase 
I dose-ﬁnding study assessing the safety, tolerability, and pharmaco-
kinetics of sunitinib in combination with gemcitabine and cisplatin as 
ﬁrst-line treatment of advanced NSCLC.
Methods: Patient eligibility criteria included histologically proven, 
stage IIIB or IV NSCLC not amenable to curative treatment; no prior 
chemotherapy except for adjuvant therapy completed more than 6 
months before study start; ECOG performance status 0 or 1; and 
adequate organ function. Planned dose levels include: oral sunitinib 
(37.5 or 50 mg/day for 2 weeks followed by 1 week off treatment [2/1 
schedule], in repeated three-week cycles) plus gemcitabine (1000 or 
1250 mg/m2 iv on days 1 and 8 of a 21-day cycle) and cisplatin (80 
mg/m2 iv on day 1 of each cycle). Sunitinib administered daily on a 
continuous dosing schedule will also be tested. Sunitinib doses are 
escalated in serial patient cohorts to determine the maximum tolerated 
dose for both schedules. Other endpoints include pharmacokinetics and 
antitumor efﬁcacy.
Results: As of October 2006, 13 patients were treated on the 2/1 
schedule, including 9 male and 4 female patients, median age 59 (range 
48-68). Six patients received sunitinib 37.5 mg + gemcitabine 1000 
mg/m2 + cisplatin 80 mg/m2, and 7 patients were treated with sunitinib 
50 mg + gemcitabine 1000 mg/m2 + cisplatin 80 mg/m2. No dose-lim-
iting toxicities were observed with sunitinib 37.5 mg, but 2 patients 
treated with sunitinib 50 mg experienced dose-limiting neutropenia and 
infection, and neutropenia, infection and thrombocytopenia, respec-
tively. Grade 3/4 hematological adverse events included neutropenia 
(n=3 at sunitinib 37.5 mg/day and n=5 at sunitinib 50 mg/day dose 
levels), thrombocytopenia (n=1 and n=5) and anemia (n=2 and n=0). 
Three patients treated at the sunitinib 50 mg/day dose level achieved a 
partial tumor response. There were no apparent drug-drug interactions 
between sunitinib and gemcitabine or cisplatin based on their systemic 
exposures in this study.
Conclusions: The combination of sunitinib (37.5 mg) given on 
schedule 2/1 with gemcitabine (1000 mg/m2) and cisplatin (80 mg/m2) 
appears safe and tolerable in this patient population with advanced 
NSCLC. The trial continues with gemcitabine escalated to 1250 mg/m2 
and with sunitinib administered on a continuous dosing schedule.
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Background: Nab-paclitaxel has eliminated many of the difﬁculties 
associated with the infusion of standard solvent-based paclitaxel (in 
cremophor). In this phase II, open label trial, patients with advanced 
(stage IIIB or IV) nonsquamous NSCLC received nab-paclitaxel and 
carboplatin in combination with bevacizumab.
Methods: Patients (N=50) enrolled between October 2005 and April 
2006. They received intravenous (IV) nab-paclitaxel 300 mg/m2, 
carboplatin IV AUC=6, and bevacizumab 15 mg/kg on Day 1 of each 
21-day cycle. Patients with CR, PR, or SD received >4 cycles of treat-
ment; however, patients with progression or intolerable toxicity were 
taken off treatment. Response rate, based on RECIST, was the primary 
endpoint.
Results: At baseline, the median age was 67 years; 80% were white 
and 56% were female. Patients received a median of 4 cycles (range, 
<1 - 6). The preliminary response rates are PR 30% and SD 48%; no 
complete responses have been noted. To date, median progression-free 
survival is 7.1 months (range, <1 - 10.6); median survival has not yet 
been reached. Grade 3-4 treatment related toxicities were neutropenia 
(52%); fatigue (19%); neuropathy (15%); thrombocytopenia (10%) 
dyspnea (6%), anorexia, constipation, febrile neutropenia, hemoptysis, 
and nausea and/or vomiting (4% each). 64% of patients are surviving. 
32 patients have come off study prior to 4 cycles due to disease pro-
gression (12%), adverse event (10%), investigator request (8%), sudden 
death (6%), and withdrawal of consent (2%); 16 patients had normal 
study completion (completed 4 cycles of therapy). 
Conclusions: The combination of nab-paclitaxel, carboplatin, and 
bevacizumab is well-tolerated, producing moderate, but manageable, 
neutropenia. This preliminary analysis indicates that the 3-drug combi-
nation has promising activity in ﬁrst-line patients with non-squamous 
NSCLC. 
This research was supported, in part, by a research grant from Abraxis 
BioScience, Inc., Santa Monica, CA.
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Background: XL647 is an orally bioavailable small molecule inhibi-
tor of multiple receptor tyrosine kinases involved in tumorigenesis, 
angiogenesis and metastasis including EGFR/ErbB1, HER2/ErbB2, 
VEGFR2/KDR, and EphB4. In addition, XL647 has preclinical activity 
in the H1975 cell line which harbors the T790M mutation in the EGFR 
gene that confers acquired resistance to erlotinib and geﬁtinib. 
Methods: This is a Simon two-stage study with a primary endpoint of 
efﬁcacy deﬁned as best conﬁrmed response rate. Adult patients (pts) 
with previously untreated advanced NSCLC (Stage IIIB with malig-
nant pleural effusion or Stage IV) with adenocarcinoma histology are 
eligible. Pts must have either an activating mutation of the EGFR gene 
in tumor tissue or meet at least one of the following three demographic 
eligibility criteria: Asian, female (F), minimal (less than 15 pack-years) 
or no smoking history (within the last 25 years). XL647 is administered 
orally as a single dose of 350 mg on days 1-5 of each 14 day cycle. 
Tumor response is assessed every 8 wks by RECIST. The mutational 
status of EGFR gene and other relevant genes in tumor tissue will be 
analyzed for genotypic correlates of response or insensitivity to XL647.
Results: Seventeen pts (12F/5M) with a median age of 62yrs (range 
45-86) have been enrolled to date. Eight pts were never-smokers, 8 had 
<15 pack years (pk-yr) smoking history, and 1 had >15 pk-yr. Four pts 
who have had a partial response (PR) and 1 with stable disease (SD) 
continue on treatment. Six pts have been discontinued due to progres-
sive disease (PD). The remaining 6 pts are too early to evaluate. To date 
EGFR gene mutations were not detected in DNA from the tumors of 4 
pts with PD as well as 1 pt with a PR and 1 pt who had SD, additional 
analysis is ongoing. The most common adverse events reported are 
grade 1 and 2 rash and diarrhea and grade 1 fatigue. A total of 4 SAEs 
have been reported in 3 patients; 1 event of grade 3 pneumonia was 
considered possibly related to study drug, the other 3 SAEs were not 
related.
Conclusions: XL647 appears to have activity and to be well-toler-
ated in a NSCLC patient population enriched for likelihood of having 
an EGFR mutation. Based upon activity seen in stage I, enrolment 
continues in the second stage of the study and updated results including 
mutational analysis of genes in tumor tissue will be presented. 
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Background: SNPs in DNA repair genes may affect response to cyto-
toxic therapy. We investigated SNPs in XPD codons 751 and 312 and 
in RRM1 -37 in 109 stage IIIA (N2) and IIIB NSCLC p treated with 
neoadjuvant chemotherapy and correlated results with event-free (EFS) 
and median (MS) survival. 
Methods: p eligible for surgery received cisplatin day (d) 1, gemcitabi-
ne d 1,8, docetaxel d 1,8,15, every 3 weeks for 3 cycles, followed by 
thoracotomy. DNA was extracted from baseline peripheral lymphocytes 
and genotyping was performed by Taqman. 
Results: Median age, 60 y (range 31-77); 92 males (84%); 45 squa-
mous cell (41%). 4 p (3.9%) attained complete response; 55 (53.9%) 
partial response. 75 p underwent surgery (62 complete, 13 incomplete 
resection); remaining 34 p were unresectable. Median follow-up was 
15.7 months (m) (range, 0.5-74). MS for p still alive is 49.8 m (range, 
6.7-74). MS: 48 m with complete resection, 13 m with incomplete 
resection, 17 m for unresected p. In the univariate analysis of sur-
vival, age <59 y (P=0.03), resection (P<0.001) and XPD312 AspAsp 
(P=0.05) emerged as predictive markers of longer survival. For all 109 
p, those with XPD312 AspAsp had longer EFS and MS than p with Asn 
variants (Table). In addition, for 51 p <59 y, EFS was longer for 24 p 
